FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_															
1. Name and Address of Reporting Person* SEIFERT RACHEL A							2. Issuer Name and Ticker or Trading Symbol COMMUNITY HEALTH SYSTEMS INC [CYH]									5. Relationship of Reporting (Check all applicable) Director Officer (give title			g Person(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) 4000 MERIDIAN BOULEVARD						3. Date of Earliest Transaction (Month/Day/Year) 02/27/2016									below) below) Executive VP and Secretary					
(Street) FRANKLIN TN 37067					4. If	Ame	endment	, Date	of Original	Filed	(Month/Day		ine) X					n		
(City) (State) (Zip)														Person						
		Tab	le I - No			_				Dis	posed o									
Da			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amour Securitie Beneficia Owned F Reported	s Illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price	Tranca		ction(s)			(5 4)		
Common S	Stock			02/27	7/2016	5			F		2,280	D	\$15	5.12	164	164,833		D		
		Т							• '		osed of, convertib			•	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code (8)		of Derive Secuence (A) of Disperse of (D	osed) r. 3, 4	er 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Titl of Set Under Deriva (Instr.			7. Title ar of Securi Underlyir Derivativ (Instr. 3 a	ties ng e Securi	D	Price of erivative ecurity nstr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab	le	Expiration Date	Title	Amou or Numb of Share	er						
Stock Options (Right to Buy)	\$32.28								02/27/20	09	02/26/2018	Common Stock	10,00	00		10,00	0	D		
Stock Options (Right to Buy)	\$18.18								02/25/20	10	02/24/2019	Common Stock	2,50	0		2,500)	D		
Stock Options (Right to Buy)	\$33.9								02/24/20	11	02/23/2020	Common Stock	7,50	00		7,500)	D		
Stock Options (Right to Buy)	\$37.96								02/23/20	12	02/22/2021	Common Stock	7,50	00		7,500)	D		
Stock Options (Right to Buy)	\$21.07								02/16/20	13	02/15/2022	Common Stock	7,50	00		7,500)	D		
Performance Based Restricted	\$0.00								(1)		(1)	Common Stock	33,33	33		33,33	4	D		
Performance Based	\$0.00								02/01/201	c(2)	02/28/2025	Common	70.00	nn		35.00	_	D		

Explanation of Responses:

- 1. Each performance based restricted share represents a contingent right to receive one share of CYH common stock. The lapsing of the restrictions is dependent on the Company meeting certain cost savings ("synergies") from the Health Management Associates, Inc. merger transaction. The award was granted on 3/01/14. The performance target on the remaining portion of the award may be met in whole or in part in the second year following the grant. There is also a time vesting element to the maximum targets of the award. If the objectives are not met, the shares will be forfeited.
- 2. Each performance based restricted share represents a contingent right to receive one share of CYH common stock. There are two elements to the lapsing of the performance-based restriction; first, the Company must achieve specified targeted amount of earnings per share from continuing operations, or net revenue from continuing operations, and if the performance objective is met, the time-vesting restrictions will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. If the performance objectives are not met, the shares will be forfeited.

Remarks:

<u>Christopher G. Cobb, Attorney</u> <u>in Fact for Rachel A. Seifert</u>

03/01/2016

** Signature of Reporting Person

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.